Session chair:
Dr Micha FRIDMAN
TEL AVIV UNIVERSITY, Ramat Aviv, Tel Aviv, Israel
08:30
Versatile Iridium Catalysts for a Broad Range of Asymmetric Transformations
Prof. Erick M. CARREIRA
ETH ZÜRICH, Zürich, Switzerland
09:20
Challenges and Synthetic Ingenuity in the Generic World
Dr Lilach HEDVATI
TEVA, Petah-Tiqva, Israel
Research field – Teva API generic R&D, Focus on development of synthetic approaches for the preparation of small molecules on the field of active pharmaceutical ingredients.
Education and former professional experience
- B.Sc. in Chemistry. Tel Aviv university, Israel 1995
- Master in Organic Chemistry: Bar Ilan university, Israel 1997
- Ph.D in Medicinal Chemistry, Bar Ilan university, Israel 2003
10:00
OC07 - Synthesis and Application of Unnatural Proline Analogues: Advanced Building Blocks for Medicinal Chemistry
Dr Pavel MYKHAILIUK
ENAMINE, Kyiv, Ukraine
Pavel Mykhailiuk was born in Kerch, Ukraine in 1984. In 2000 he won a bronze medal at 32nd International Chemistry Olympiads, IChO (Copenhagen, Denmark). In 2008 he received PhD in Biochemistry at Technical University of Karlsruhe (KIT, Germany) after working with Prof. Anne Ulrich. Thereafter, he joined the Kyiv National Taras Shevchenko University (Ukraine), where he obtained PhD in Chemistry under the supervision of Prof. Igor Komarov. Since then Pavel holds a position Senior Scientist at this University. Independently, in 2009 he joined “Enamine LTD” company (Ukraine), where in 2011 he became a head of custom synthesis department; and since 2013 he holds a position of Chief Scientific Officer (CSO). Pavel´s research interests include fluorine-containing compounds, conformationally restricted molecules, 3D-shaped unnatural scaffolds and their application in medicinal chemistry. He is co-author of more than 80 research manuscripts, 1 patent and 1 book chapter. In 2014 he was selected as a runner up of EFMC Prize for a Young Medicinal Chemist in Industry.
10:15
Coffee break and Exhibition
10:45
Evolving GPCRs to Favorable Biophysical Properties: Enabling Drug Screening and Structural Studies
Prof. Andreas PLÜCKTHUN
UNIVERSITY OF ZÜRICH, Zurich, Switzerland
Andreas Plückthun studied chemistry at the University of Heidelberg, and received his PhD at the University of California at San Diego. He was a postdoctoral fellow at the Chemistry Department of Harvard University. He became group leader at the Genzentrum and Max-Planck-Institut für Biochemie in Martinsried. He was appointed to the University of Zurich as a Full Professor of Biochemistry in 1993. He has written over 370 publications, which have been cited over 20,000 times (h-factor 84). In 2003, he was elected to the German Academy of Science (Leopoldina).
He received the Young Investigator's Award of the German Industry Fund, was elected member of EMBO, and is recipient of the Karl-Heinz-Beckurts-Prize (Munich, Germany), finalist in the World Technology Awards 2001 (London, UK), recipient of the JP Morgan Chase Health Award (San Jose, USA), the Wilhelm Exner Medal (Vienna, Austria), and together with his colleagues, the Swiss Technology Award (Bern, Switzerland) and the deVigier Award. He is co-founder and Scientific Advisor of Morphosys AG (Martinsried, Germany) and of Molecular Partners AG (Zürich, Switzerland), for which he is also a board member.
His research field is protein engineering. His lab combines directed evolution, biophysics and biomedical applications. His major contributions to the field include antibody engineering, the development of true Darwinian in vitro evolution technologies, the development of new binding proteins (DARPins) and the evolution of highly stable G-protein coupled receptors.
11:35
The Power of Integrated Technological Platforms to Advance Science and Medicine
Dr Berta STRULOVICI
WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel
Berta Strulovici, Ph.D.
Director, Nancy and Steven Grand Israel National Center for Personalized
Medicine, Weizmann Institute of Science, Rehovot, Israel
Dr. Berta Strulovici received her Ph.D from The Weizmann Institute of
Science in Rehovot, Israel. She then conducted postdoctoral research under
the guidance of Professor Robert J. Lefkowitz at the Howard Hughes
Medical Institute Duke University Medical School in Durham, NC, USA.
Berta has a track record in building and leading outstanding, productive
teams, while integrating innovative processes into seamless, successful
enterprises in start-up and large Pharma environments. Berta served as
Director R&D at Tularik, the first start- up focused on targeting transcription
factors in disease. At Merck Research Laboratories (MRL) in North Wales,
PA, Berta served in positions of increased responsibilities over a period of
12 years. As Vice President of Basic Research in charge of building a stateof-
the-art Center of Excellence for early drug discovery for Merck
Worldwide, she and her team were involved in the discovery of lead
compounds that are currently in clinical trials for various diseases. In 2012,
Berta undertook a new role as Director of the Nancy and Steven Grand Israel
National Center for Personalized Medicine, at the Weizmann Institute of
Science. The Center has been implementing novel technologies in
genomics, proteomics, bioinformatics and Chemical Biology to enable and
advance Personalized Medicine and life sciences in Israel.
12:15
OC08 - Necrosis: Cellular Mechanisms and Treatment
Prof. Amnon ALBECK
BAR ILAN UNIVERSITY, Ramat Gan, Israel
Prof. Albeck did his PhD with Prof. Mudi Sheves in the Department of Organic Chemistry, The Weizmann Institute of Science in Israel. He then went for post-doctoral research with Prof. Abeles in Brandeis University, USA.
Prof. Albeck has been a faculty member in the Department of Chemistry at Bar Ilan University since 1990. He is the head of the Julius Spokojny Bioorganic Chemistry Laboratory and a member of the Marcus Center for Medicinal Chemistry.
Prof. Albeck was the Chairman of the Department of Chemistry, and he now serves as the Vice-Rector of Bar Ilan University.
His main research interests are in the fields of enzyme mechanism and inhibition, drug design, and synthetic chemistry of peptides and peptidomimetics.
12:45
Session chair:
Prof. Ilan MAREK
ISRAEL INSTITUTE OF TECHNOLOGY, Haifa, Israel
14:00
OC09 - Catalytic Asymmetric Synthesis of Caprazamycin B and Caprazol
Dr Takumi WATANABE
INSTITUTE OF MICROBIAL CHEMISTRY (BIKAKEN), Tokyo, Japan
Date of birth, 5 Aug 1968
1991 Graduated from The University of Tokyo (Professor Masaji. Ohno)
1993 Obtained master degree from The University of Tokyo (Professor Masakatsu.
Shibasaki)
1993 Joined to Institute of Microbial Chemistry as a researcher
2000 Obtained Ph. D. (Keio University (Professor Kazuo Umezawa))
2002-2004 Post doctoral work at ETH Zurich (Professor Erick M. Carreira)
2004 Back to Institute of Microbial Chemistry
2010 Promoted to Chief Researcher of Institute of Microbial Chemistry (Laboratory of
Synthetic Organic Chemistry, Professor Masakatsu. Shibasaki)
2015- Promoted to Laboratory Head for Laboratory of Synthetic Organic Chemistry in
Institute of Microbial Chemistry (Professor M. Shibasaki)
14:15
OC10 - Synthesis of Archazolid F and Other Novel Archazolids: Highly Potent V-Atpase Inhibitors
Mr Stephan SCHEEFF
UNIVERSITY OF BONN, Bonn, Germany
Stephan Scheeff was born in 1988 in south Germany. In 2008 he moved to Berlin and started his studies in chemistry at the Humbold-University of Berlin. In 2014 he finished his diploma under the supervision of Prof. Dr. Rainer Mahrwald. His research topic was direct asymmetric organocatalytic aldol reactions catalyzed by amino acids. In this time he was funded and supported by the Friedrich-Ebert-Foundation. Since January 2015 he has been working in the group of Prof. Dr. Dirk Menche at the University of Bonn for his PhD studies. His research interests include the total synthesis and derivatisation of natural products.
Until now, he is working with archazolids which is an interesting natural product with an inhibitor potency against V-ATPase.
14:30
OC11 - Protecting Group-Free Strategies for The Synthesis of Nucleosides
Mr Mike DOWNEY
INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY, Prague-6, Czech Republic
I was born in Calgary, Alberta, Canada and after high school I moved to the University of Alberta in Edmonton where I completed undergraduate studies in pharmacology and masters studies in chemical biology under the supervision of Dr. Chris Cairo. In 2013, after the completion of my MSc degree, my lust for travelling brought me to Prague to pursue a PhD in the group of Prof. Michal Hocek at the Institute of Organic Chemistry and Biochemistry where I am currently in my 3rd year of study.
14:45
OC12 - Development of Anti-Influenza Drugs
Prof. Jim-Min FANG
NATIONAL TAIWAN UNIVERSITY, Taipei, Taiwan
Dr. Jim-Min Fang received his B. S. degree in 1974 from the National Taiwan University (Department of Chemistry) and Ph. D. degree in 1980 from Yale University. After finishing postdoctoral research in Columbia University and in the Suntory Institute for Bioorganic Research (Osaka), he joined the Department of Chemistry, National Taiwan University, as Associated Professor in 1982, and promoted to Professor in 1986. He served as departmental chairman from 1993 to 1996. He is now a Distinguished Professor of National Taiwan University and TBF Chair in Biotechnology. He also holds a joint appointment in the Genomics Research Center, Academia Sinica.
Professor Fang has obtained several prestige awards: National Science Council Award for Outstanding Research (1987–96) and Invited Principal Investigator (1997–2003), Sun Yat-Sen Award for Academic Publications (1992), Chinese Chemical Society Award (1997), National Taiwan University Award for Teaching Excellence (1999), Chair Professor of Foundation for Advancement of Outstanding Scholarship (1999–2004), TienTe Lee Award for Outstanding Medical and Pharmaceutical Science and Technology (2009), Ministry of Education’s Academic Award (2009), and TBF Chair in Biotechnology of Taiwan Bio-Development Foundation (2014–present).
His current research interests are organic synthesis and chemical biology, including new synthetic methods, asymmetric catalysis, biomolecular recognition, natural products and drug discovery. He is the author and co-author of over 240 publications, 20 patents, and three books. He also serves in scientific advisory board of several research institutes and pharmaceutical companies.
15:00
OC13 - Cross Metathesis of Sulfonamides and Sulfoxides
Mr Adam RAJKIEWICZ
UNIVERSITY OF WARSAW, Warsaw, Poland
I am a second year Master student in Chemistry Department, University of Warsaw, Poland. I am carrying out my research in Laboratory of Organometallic Synthesis, Biological an Chemical Sciences Centre, in group of prof. Karol Grela. Our research aims to organometallic chemistry, especially reaction called olefin metathesis, catalysed by transition metals complexes. My work is focused on developing a new methodology, activities and apllications of olefin metathesis.
15:15
Coffee break and Exhibition
15:45
The Barry Cohen Award for Excellence in Medicinal Chemistry Prize Ceremony
Synthesis-Informed Design Directed at Transformative Therapies: Eradication of Hiv/Aids, Alzheimer's Disease and Resistant Cancer
Prof. Paul A. WENDER
STANFORD UNIVERSITY, Stanford, United States
Paul Wender (Yale PhD; Columbia NIH Postdoctoral Fellow) served on the faculty at Harvard University and is currently the Bergstrom Professor of Chemistry and Professor of Chemical and Systems Biology (by courtesy, Stanford Medical School). He is an advisor to the Stanford Molecular Imaging Program, the Stanford Human Chemistry Institute (Chem-H), and several biotech companies and institutes and affiliated with the Bio-X Program, the Center for Molecular Analysis and Design, the Quantitative Chemical Biology Program, the Comprehensive Cancer Center, the Cancer Nanotechnology Program, the Molecular Therapeutics Program, and the NIH Biotechnology Training Program. His research involves studies in chemistry, biology, medicine, and materials science with an emphasis on computer-based design, new reactions, the ideal synthesis, step economy, and function oriented synthesis directed at imaging, drug delivery, resistant cancer, immunotherapy, HIV/AIDS eradication, and Alzheimer’s disease.
16:30
Closing remarks
Prof. Ilan MAREK
ISRAEL INSTITUTE OF TECHNOLOGY, Haifa, Israel
20:00